Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICCRT: PRO-based Tislelizumab Strategy in Esophageal Cancer
NCT05596890Phase 2Unknown
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Nov 2022
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Pathologic Complete Response Rate. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05596890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05596890.